

# Dennis Mccarty

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1923352/publications.pdf>

Version: 2024-02-01

168  
papers

5,871  
citations

57758

44  
h-index

106344

65  
g-index

173  
all docs

173  
docs citations

173  
times ranked

4570  
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Care-Based Models for the Treatment of Opioid Use Disorder. <i>Annals of Internal Medicine</i> , 2017, 166, 268.	3.9	224
2	Self-help organizations for alcohol and drug problems: Toward evidence-based practice and policy. <i>Journal of Substance Abuse Treatment</i> , 2004, 26, 151-158.	2.8	206
3	The Network for the Improvement of Addiction Treatment (NIATx): Enhancing access and retention. <i>Drug and Alcohol Dependence</i> , 2007, 88, 138-145.	3.2	186
4	Barriers and facilitators affecting the implementation of substance use screening in primary care clinics: a qualitative study of patients, providers, and staff. <i>Addiction Science &amp; Clinical Practice</i> , 2018, 13, 8.	2.6	162
5	Research to practice. <i>Journal of Substance Abuse Treatment</i> , 2003, 24, 1-11.	2.8	140
6	Bringing Buprenorphine-Naloxone Detoxification to Community Treatment Providers: The NIDA Clinical Trials Network Field Experience. <i>American Journal on Addictions</i> , 2004, 13, S42-S66.	1.4	130
7	Methadone, buprenorphine and preferences for opioid agonist treatment: A qualitative analysis. <i>Drug and Alcohol Dependence</i> , 2016, 160, 112-118.	3.2	121
8	Attitudes toward the integration of smoking cessation treatment into drug abuse clinics. <i>Journal of Substance Abuse Treatment</i> , 2007, 32, 53-60.	2.8	107
9	Organizational Readiness for Change and opinions toward treatment innovations. <i>Journal of Substance Abuse Treatment</i> , 2007, 33, 183-192.	2.8	104
10	Which elements of improvement collaboratives are most effective? A cluster-randomized trial. <i>Addiction</i> , 2013, 108, 1145-1157.	3.3	104
11	Patient-reported pathways to opioid use disorders and pain-related barriers to treatment engagement. <i>Journal of Substance Abuse Treatment</i> , 2017, 73, 47-54.	2.8	88
12	Substance Use Disorders and COVID-19: Multi-Faceted Problems Which Require Multi-Pronged Solutions. <i>Frontiers in Psychiatry</i> , 2020, 11, 714.	2.6	84
13	Replication and sustainability of improved access and retention within the Network for the Improvement of Addiction Treatment. <i>Drug and Alcohol Dependence</i> , 2008, 98, 63-69.	3.2	78
14	Role of the Hospital in the 21st Century Opioid Overdose Epidemic: The Addiction Medicine Consult Service. <i>Journal of Addiction Medicine</i> , 2019, 13, 104-112.	2.6	78
15	Direct Care Workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs. <i>Psychiatric Services</i> , 2007, 58, 181-190.	2.0	78
16	Substance abuse treatment for pregnant women: a window of opportunity?. <i>Addictive Behaviors</i> , 1998, 23, 239-249.	3.0	75
17	Direct Care Workers in the National Drug Abuse Treatment Clinical Trials Network: Characteristics, Opinions, and Beliefs. <i>Psychiatric Services</i> , 2007, 58, 181-190.	2.0	73
18	Client and counselor attitudes toward the use of medications for treatment of opioid dependence. <i>Journal of Substance Abuse Treatment</i> , 2007, 32, 207-215.	2.8	71

#	ARTICLE	IF	CITATIONS
19	Research to practice: adoption of naltrexone in alcoholism treatment. <i>Journal of Substance Abuse Treatment</i> , 2003, 24, 1-11.	2.8	66
20	The first decade of the National Drug Abuse Treatment Clinical Trials Network: Bridging the gap between research and practice to improve drug abuse treatment. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S4-S13.	2.8	65
21	Making "Stone Soup" Improvements in Clinic Access and Retention in Addiction Treatment. <i>Joint Commission Journal on Quality and Patient Safety</i> , 2007, 33, 95-103.	0.7	62
22	Predictors of outcome for short-term medically supervised opioid withdrawal during a randomized, multicenter trial of buprenorphine-naloxone and clonidine in the NIDA clinical trials network drug and alcohol dependence. <i>Drug and Alcohol Dependence</i> , 2009, 99, 28-36.	3.2	59
23	Use of the addiction severity index with homeless substance abusers. <i>Journal of Substance Abuse Treatment</i> , 1994, 11, 359-365.	2.8	57
24	Treatment and Prevention of Opioid Use Disorder: Challenges and Opportunities. <i>Annual Review of Public Health</i> , 2018, 39, 525-541.	17.4	57
25	Adoption of naltrexone to treat alcohol dependence. <i>Journal of Substance Abuse Treatment</i> , 2005, 28, 273-280.	2.8	56
26	Patients' Reasons for Choosing Office-Based Buprenorphine: Preference for Patient-Centered Care. <i>Journal of Addiction Medicine</i> , 2010, 4, 204-210.	2.6	56
27	Days to treatment and early retention among patients in treatment for alcohol and drug disorders. <i>Addictive Behaviors</i> , 2011, 36, 643-647.	3.0	56
28	Alcoholism, drug abuse, and the homeless.. <i>American Psychologist</i> , 1991, 46, 1139-1148.	4.2	56
29	Early Performance in Medicaid Accountable Care Organizations. <i>JAMA Internal Medicine</i> , 2017, 177, 538.	5.1	55
30	Changing Contraceptive Usage Intentions: A Test of the Fishbein Model of Intention1. <i>Journal of Applied Social Psychology</i> , 1981, 11, 192-211.	2.0	54
31	Item banks for alcohol use from the Patient-Reported Outcomes Measurement Information System (PROMIS®): Use, consequences, and expectancies. <i>Drug and Alcohol Dependence</i> , 2013, 130, 167-177.	3.2	54
32	Using State Information Systems for Drug Abuse Services Research. <i>American Behavioral Scientist</i> , 1998, 41, 1090-1106.	3.8	52
33	Improving Care for the Treatment of Alcohol and Drug Disorders. <i>Journal of Behavioral Health Services and Research</i> , 2009, 36, 52-60.	1.4	52
34	Extended-Release Naltrexone: A Qualitative Analysis of Barriers to Routine Use. <i>Journal of Substance Abuse Treatment</i> , 2016, 62, 68-73.	2.8	52
35	Association of Prescription Drug Monitoring Program Use With Opioid Prescribing and Health Outcomes: A Comparison of Program Users and Nonusers. <i>Journal of Pain</i> , 2018, 19, 166-177.	1.4	52
36	Substance Abuse Intensive Outpatient Programs: Assessing the Evidence. <i>Psychiatric Services</i> , 2014, 65, 718-726.	2.0	51

#	ARTICLE	IF	CITATIONS
37	Feasibility and safety of extended-release naltrexone treatment of opioid and alcohol use disorder in HIV clinics: a pilot/feasibility randomized trial. <i>Addiction</i> , 2017, 112, 1036-1044.	3.3	51
38	Management of Suspected Opioid Overdose With Naloxone in Out-of-Hospital Settings. <i>Annals of Internal Medicine</i> , 2017, 167, 867.	3.9	51
39	Comparing Canadian and United States opioid agonist therapy policies. <i>International Journal of Drug Policy</i> , 2019, 74, 257-265.	3.3	50
40	Challenges in the adoption of new pharmacotherapeutics for addiction to alcohol and other drugs. , 2005, 108, 119-128.		49
41	Extended-release naltrexone for alcohol and opioid dependence: A meta-analysis of healthcare utilization studies. <i>Journal of Substance Abuse Treatment</i> , 2014, 47, 113-121.	2.8	49
42	Training rural practitioners to use buprenorphine. <i>Journal of Substance Abuse Treatment</i> , 2004, 26, 203-208.	2.8	47
43	A qualitative study of the adoption of buprenorphine for opioid addiction treatment. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 390-401.	2.8	47
44	Treatment programs in the National Drug Abuse Treatment Clinical Trials Network. <i>Drug and Alcohol Dependence</i> , 2008, 92, 200-207.	3.2	46
45	Reasons for drinking: Motivational patterns and alcohol use among college students. <i>Addictive Behaviors</i> , 1984, 9, 185-188.	3.0	45
46	From research to the real world: Buprenorphine in the decade of the Clinical Trials Network. <i>Journal of Substance Abuse Treatment</i> , 2010, 38, S53-S60.	2.8	45
47	Improving Adherence to HIV Quality of Care Indicators in Persons With Opioid Dependence: The Role of Buprenorphine. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2011, 56, S83-S90.	2.1	45
48	American Indians with Substance Use Disorders: Treatment Needs and Comorbid Conditions. <i>American Journal of Drug and Alcohol Abuse</i> , 2012, 38, 498-504.	2.1	44
49	Behavioral Health Insurance Parity: Does Oregon's Experience Presage the National Experience With the Mental Health Parity and Addiction Equity Act?. <i>American Journal of Psychiatry</i> , 2012, 169, 31-38.	7.2	43
50	Oregon's Medicaid transformation: An innovative approach to holding a health system accountable for spending growth. <i>Healthcare</i> , 2014, 2, 163-167.	1.3	43
51	Understanding opioid overdose characteristics involving prescription and illicit opioids: A mixed methods analysis. <i>Drug and Alcohol Dependence</i> , 2016, 167, 49-56.	3.2	43
52	Opioid Agonist Therapy During Hospitalization Within the Veterans Health Administration: a Pragmatic Retrospective Cohort Analysis. <i>Journal of General Internal Medicine</i> , 2020, 35, 2365-2374.	2.6	43
53	Welfare Reform and the Changing Landscape of Substance Abuse Services for Low-Income Women. <i>Alcoholism: Clinical and Experimental Research</i> , 2000, 24, 1298-1311.	2.4	42
54	Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2015, 10, 13.	2.2	42

#	ARTICLE	IF	CITATIONS
55	Opioid use disorder and treatment: challenges and opportunities. BMC Health Services Research, 2019, 19, 884.	2.2	42
56	The costs of crime and the benefits of substance abuse treatment for pregnant women. Journal of Substance Abuse Treatment, 2000, 19, 445-458.	2.8	41
57	Addiction Treatment Agencies'™ Use of Data: A Qualitative Assessment. Journal of Behavioral Health Services and Research, 2006, 33, 394-407.	1.4	41
58	Possible barriers to enrollment in substance abuse treatment among a diverse sample of Asian Americans and Pacific Islanders: Opinions of treatment clients. Journal of Substance Abuse Treatment, 2013, 44, 309-315.	2.8	41
59	Measures Such As Interstate Cooperation Would Improve The Efficacy Of Programs To Track Controlled Drug Prescriptions. Health Affairs, 2013, 32, 603-613.	5.2	40
60	Medicaid Coverage, Methadone Maintenance, and Felony Arrests: Outcomes of Opiate Treatment in Two States. Journal of Addictive Diseases, 2009, 28, 89-102.	1.3	39
61	Reducing HIV-Related Risk Behaviors Among Injection Drug Users in Residential Detoxification. AIDS and Behavior, 2011, 15, 30-44.	2.7	39
62	Therapist predictors of treatment delivery fidelity in a community-based trial of 12-step facilitation. American Journal of Drug and Alcohol Abuse, 2013, 39, 304-311.	2.1	37
63	Methadone maintenance and the cost and utilization of health care among individuals dependent on opioids in a commercial health plan. Drug and Alcohol Dependence, 2010, 111, 235-240.	3.2	36
64	Substance Use and the Quality of Patient-Provider Communication in HIV Clinics. AIDS and Behavior, 2011, 15, 832-841.	2.7	36
65	Methadone Maintenance and State Medicaid Managed Care Programs. Milbank Quarterly, 1999, 77, 341-362.	4.4	35
66	Management practices in substance abuse treatment programs. Journal of Substance Abuse Treatment, 2009, 37, 79-89.	2.8	35
67	Improving Quality of Care in Substance Abuse Treatment Using Five key Process Improvement Principles. Journal of Behavioral Health Services and Research, 2012, 39, 234-244.	1.4	35
68	Item banks for substance use from the Patient-Reported Outcomes Measurement Information System (PROMIS Å®): Severity of use and positive appeal of use. Drug and Alcohol Dependence, 2015, 156, 184-192.	3.2	35
69	Costs of care for persons with opioid dependence in commercial integrated health systems. Addiction Science & Clinical Practice, 2014, 9, 16.	2.6	33
70	Frequency of Cannabis Use Among Primary Care Patients in Washington State. Journal of the American Board of Family Medicine, 2017, 30, 795-805.	1.5	33
71	â€œNow hospital leaders are paying attentionâ€: A qualitative study of internal and external factors influencing addiction consult services. Journal of Substance Abuse Treatment, 2020, 110, 59-65.	2.8	32
72	Detoxification centers: Who's in the revolving door?. Journal of Behavioral Health Services and Research, 2000, 27, 245-256.	1.4	31

#	ARTICLE	IF	CITATIONS
73	Understanding attitudes toward use of medication in substance abuse treatment: A multilevel approach.. Psychological Services, 2009, 6, 74-84.	1.5	30
74	Opioid Treatment Programs, Telemedicine and COVID-19: A Scoping Review. Substance Abuse, 2022, 43, 539-546.	2.3	30
75	Substance abuse treatment management information systems: Balancing federal, state, and service provider needs. Journal of Mental Health Administration, 1992, 19, 5-20.	1.1	29
76	Substance abuse treatment providers' involvement in research is associated with willingness to use findings in practice. Journal of Substance Abuse Treatment, 2010, 39, 188-194.	2.8	29
77	Disparities in Alcohol, Drug Use, and Mental Health Condition Prevalence and Access to Care in Rural, Isolated, and Reservation Areas: Findings From the South Dakota Health Survey. Journal of Rural Health, 2016, 32, 287-302.	2.9	29
78	Facilitating outpatient treatment entry following detoxification for injection drug use: A multisite test of three interventions.. Psychology of Addictive Behaviors, 2009, 23, 260-270.	2.1	28
79	Advancing Recovery: Implementing Evidence-Based Treatment for Substance Use Disorders at the Systems Level. Journal of Studies on Alcohol and Drugs, 2012, 73, 413-422.	1.0	28
80	Employing policy and purchasing levers to increase the use of evidence-based practices in community-based substance abuse treatment settings: Reports from single state authorities. Evaluation and Program Planning, 2011, 34, 366-374.	1.6	27
81	Performance measures for outpatient substance abuse services: Group versus individual counseling. Journal of Substance Abuse Treatment, 2003, 25, 271-278.	2.8	26
82	The Perceived Impact of 42 CFR Part 2 on Coordination and Integration of Care: A Qualitative Analysis. Psychiatric Services, 2017, 68, 245-249.	2.0	26
83	Barriers and facilitators to recruitment and enrollment of HIV-infected individuals with opioid use disorder in a clinical trial. BMC Health Services Research, 2019, 19, 862.	2.2	26
84	Rural opioid treatment program patient perspectives on take-home methadone policy changes during COVID-19: a qualitative thematic analysis. Addiction Science & Clinical Practice, 2021, 16, 72.	2.6	26
85	Treatment retention, return to use, and recovery support following COVID-19 relaxation of methadone take-home dosing in two rural opioid treatment programs: A mixed methods analysis. Journal of Substance Abuse Treatment, 2022, 141, 108801.	2.8	26
86	A multilevel approach to predicting community addiction treatment attitudes about contingency management. Journal of Substance Abuse Treatment, 2012, 42, 213-221.	2.8	24
87	Predicting outpatient treatment entry following detoxification for injection drug use: The impact of patient and program factors. Journal of Substance Abuse Treatment, 2010, 38, S87-S96.	2.8	23
88	The Concentration of Opioid Prescriptions by Providers and Among Patients in the Oregon Medicaid Program. Psychiatric Services, 2016, 67, 397-404.	2.0	23
89	Effects of Managed Care on Programs and Practices for the Treatment of Alcohol and Drug Dependence. , 2002, 15, 51-71.		23
90	The Impact of Substance Abuse Treatment Modality on Birth Weight and Health Care Expenditures. Journal of Psychoactive Drugs, 2001, 33, 57-66.	1.7	22

#	ARTICLE	IF	CITATIONS
91	Community-based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions. <i>Evaluation and Program Planning</i> , 2011, 34, 356-365.	1.6	22
92	Disseminating quality improvement: study protocol for a large cluster-randomized trial. <i>Implementation Science</i> , 2011, 6, 44.	6.9	22
93	A Longitudinal Study of State Strategies and Policies to Accelerate Evidence-Based Practices in the Context of Systems Transformation. <i>Health Services Research</i> , 2015, 50, 1125-1145.	2.0	22
94	Interpretation and integration of the federal substance use privacy protection rule in integrated health systems: A qualitative analysis. <i>Journal of Substance Abuse Treatment</i> , 2019, 97, 41-46.	2.8	22
95	Article Commentary: Research Priorities for Expanding access to Methadone Treatment for Opioid use Disorder in the United States: A National Institute on Drug Abuse Clinical Trials Network Task Force Report. <i>Substance Abuse</i> , 2021, 42, 245-254.	2.3	22
96	Understanding the importance of organizational and system variables on addiction treatment services within criminal justice settings. <i>Drug and Alcohol Dependence</i> , 2009, 103, S91-S93.	3.2	21
97	Priorities for policy research on treatments for alcohol and drug use disorders. <i>Journal of Substance Abuse Treatment</i> , 2010, 39, 87-95.	2.8	21
98	Barriers to Buprenorphine Expansion in Ohio: A Time-Elapsed Qualitative Study. <i>Journal of Psychoactive Drugs</i> , 2019, 51, 272-279.	1.7	21
99	Mobile methadone medication units: A brief history, scoping review and research opportunity. <i>Journal of Substance Abuse Treatment</i> , 2021, 129, 108483.	2.8	20
100	Buprenorphine and HIV Primary Care: Report of a Forum for Collaborative HIV Research Workshop. <i>Clinical Infectious Diseases</i> , 2006, 43, S254-S257.	5.8	19
101	Does treatment fidelity predict client outcomes in 12-Step Facilitation for stimulant abuse?. <i>Drug and Alcohol Dependence</i> , 2014, 134, 330-336.	3.2	19
102	The Iowa Managed Substance Abuse Care Plan: Access, utilization, and expenditures for medicaid recipients. <i>Journal of Behavioral Health Services and Research</i> , 2003, 30, 18-25.	1.4	18
103	How did the introduction of managed care for the uninsured in Iowa affect the use of substance abuse services?. <i>Journal of Behavioral Health Services and Research</i> , 2003, 30, 26-40.	1.4	18
104	Implementation of MET/CBT 5 for Adolescents. <i>Journal of Behavioral Health Services and Research</i> , 2008, 35, 304-314.	1.4	18
105	Clinician attitudes, social norms and intentions to use a computer-assisted intervention. <i>Journal of Substance Abuse Treatment</i> , 2013, 44, 433-437.	2.8	18
106	State substance abuse and mental health managed care evaluation program. <i>Journal of Behavioral Health Services and Research</i> , 2003, 30, 7-17.	1.4	17
107	The relationship of therapeutic alliance and treatment delivery fidelity with treatment retention in a multisite trial of twelve-step facilitation.. <i>Psychology of Addictive Behaviors</i> , 2015, 29, 106-113.	2.1	16
108	Medicaid expansion and treatment for opioid use disorders in Oregon: an interrupted time-series analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2019, 14, 31.	2.6	16

#	ARTICLE	IF	CITATIONS
109	Office-Based Methadone Treatment for Opioid Use Disorder and Pharmacy Dispensing: A Scoping Review. <i>American Journal of Psychiatry</i> , 2021, 178, 804-817.	7.2	16
110	Guidelines for Alcohol Abuse Prevention on the College Campus: Overcoming the Barriers to Program Success. <i>Journal of Higher Education</i> , 1981, 52, 399.	2.7	14
111	A Business Case for Quality Improvement in Addiction Treatment: Evidence from the NIATx Collaborative. <i>Journal of Behavioral Health Services and Research</i> , 2012, 39, 91-100.	1.4	14
112	HIV infection among people who inject drugs: The challenge of racial/ethnic disparities.. <i>American Psychologist</i> , 2013, 68, 274-285.	4.2	14
113	Oregon's strategy to confront prescription opioid misuse: a case study. <i>Journal of Substance Abuse Treatment</i> , 2015, 48, 91-95.	2.8	14
114	Making the business case for an addiction medicine consult service: a qualitative analysis. <i>BMC Health Services Research</i> , 2019, 19, 822.	2.2	14
115	The Substance Abuse Counseling Workforce: Education, Preparation, and Certification. <i>Substance Abuse</i> , 2011, 32, 180-190.	2.3	13
116	An Item Bank for Abuse of Prescription Pain Medication from the Patient-Reported Outcomes Measurement Information System (PROMIS <sup>®</sup> ). <i>Pain Medicine</i> , 2017, 18, pnw233.	1.9	13
117	Promoting Adoption of Medication for Opioid and Alcohol Use Disorders Through System Change. <i>Journal of Studies on Alcohol and Drugs</i> , 2017, 78, 735-744.	1.0	13
118	Public sector managed care for substance abuse treatment: Opportunities for health services research. <i>Journal of Behavioral Health Services and Research</i> , 2001, 28, 143-154.	1.4	12
119	Performance measurement for systems treating alcohol and drug use disorders. <i>Journal of Substance Abuse Treatment</i> , 2007, 33, 353-354.	2.8	12
120	A Qualitative Analysis of Family Involvement in Prescribed Opioid Medication Monitoring among Individuals who Have Experienced Opioid Overdoses. <i>Substance Abuse</i> , 2016, 37, 96-103.	2.3	12
121	Use of single IRBs for multi-site studies: A case report and commentary from a National Drug Abuse Treatment Clinical Trials Network study. <i>Contemporary Clinical Trials Communications</i> , 2019, 14, 100319.	1.1	12
122	Alcohol, sexual arousal, and the transfer of excitation.. <i>Journal of Personality and Social Psychology</i> , 1982, 42, 977-988.	2.8	12
123	Expanding Access to Medications for Opioid Use Disorder: Program and Policy Approaches from Outside the Veterans Health Administration. <i>Journal of General Internal Medicine</i> , 2020, 35, 886-890.	2.6	11
124	Substance abuse treatment and HIV services: Massachusetts' policies and programs. <i>Journal of Substance Abuse Treatment</i> , 1996, 13, 429-438.	2.8	10
125	The Severity Index. <i>Alcoholism Treatment Quarterly</i> , 2001, 19, 49-64.	0.8	10
126	Improving substance abuse data systems to measure "waiting time to treatment": Lessons learned from a quality improvement initiative. <i>Health Informatics Journal</i> , 2011, 17, 256-265.	2.1	10



#	ARTICLE	IF	CITATIONS
127	Predictors of Substance use Treatment Initiation and Engagement among Adult and Adolescent Medicaid Recipients. <i>Substance Abuse</i> , 2019, 40, 285-291.	2.3	10
128	HIV clinicâ€based extendedâ€release naltrexone versus treatment as usual for people with HIV and opioid use disorder: a nonâ€blinded, randomized nonâ€inferiority trial. <i>Addiction</i> , 2022, 117, 1961-1971.	3.3	10
129	Nine Demonstration Grants:. <i>Alcoholism Treatment Quarterly</i> , 1990, 7, 1-9.	0.8	9
130	A Highâ€Resolution Analysis of Process Improvement: Use of Quantile Regression for Wait Time. <i>Health Services Research</i> , 2013, 48, 333-347.	2.0	9
131	Public Health Policy Strategies to Address the Opioid Epidemic. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 959-962.	4.7	8
132	Quality Metrics and Systems Transformation: Are We Advancing Alcohol and Drug Screening in Primary Care?. <i>Health Services Research</i> , 2018, 53, 1702-1726.	2.0	8
133	Access to treatment for alcohol use disorders following Oregon's health care reforms and Medicaid expansion. <i>Journal of Substance Abuse Treatment</i> , 2018, 94, 24-28.	2.8	8
134	The payer's role in addressing the opioid epidemic: It's more than money. <i>Journal of Substance Abuse Treatment</i> , 2019, 101, 72-78.	2.8	8
135	Hospital policies for opioid use disorder treatment: A policy content analysis and environmental scan checklist. <i>General Hospital Psychiatry</i> , 2021, 70, 18-24.	2.4	7
136	Development of a Multilevel Framework to Increase Use of Targeted Evidence-Based Practices in Addiction Treatment Clinics. <i>Public Health Frontier</i> , 2013, 2, 11-20.	0.1	7
137	Charting a path between research and practice in alcoholism treatment. <i>Alcohol Research</i> , 2006, 29, 5-10.	1.0	7
138	A residence hall tavern as a collegiate alcohol abuse prevention activity. <i>Addictive Behaviors</i> , 1983, 8, 105-108.	3.0	6
139	The Use of Health Information Technology in Publicly-Funded U. S. Substance Abuse Treatment Agencies. <i>Contemporary Drug Problems</i> , 2010, 37, 315-339.	1.6	6
140	Testing use of payers to facilitate evidence-based practice adoption: protocol for a cluster-randomized trial. <i>Implementation Science</i> , 2013, 8, 50.	6.9	6
141	Does Medical Cannabis Reduce Use of Prescription Opioids?. <i>American Journal of Psychiatry</i> , 2018, 175, 6-7.	7.2	6
142	Overcoming Barriers to Adopting and Implementing Pharmacotherapy: the Medication Research Partnership. <i>Journal of Behavioral Health Services and Research</i> , 2019, 46, 330-339.	1.4	6
143	Frequency and recency of non-medical opioid use and death due to overdose or suicide among individuals assessed for risky substance use: A national registry study in Sweden. <i>Journal of Substance Abuse Treatment</i> , 2022, 134, 108567.	2.8	6
144	Between despair and hope: health services research on treatment of alcohol abuse. <i>Addiction</i> , 2000, 95, 439-447.	3.3	5

#	ARTICLE	IF	CITATIONS
145	Health Services Research for Drug and Alcohol Treatment and Prevention. <i>Journal of Drug Issues</i> , 2009, 39, 197-208.	1.2	5
146	Differences in the Delivery of Medications for Opioid use Disorder during Hospitalization by Racial Categories: A Retrospective Cohort Analysis;. <i>Substance Abuse</i> , 2022, 43, 1251-1259.	2.3	5
147	Between despair and hope: health services research on treatment of alcohol abuse. <i>Addiction</i> , 2000, 95, 439-447.	3.3	4
148	What Influences Participation in QI? A Randomized Trial of Addiction Treatment Organizations. <i>Journal for Healthcare Quality: Official Publication of the National Association for Healthcare Quality</i> , 2015, 37, 342-353.	0.7	4
149	Toward a Patient Registry for Cannabis Use: An Exploratory Study of Patient Use in an Outpatient Health-Care Clinic in Oregon. <i>World Medical and Health Policy</i> , 2017, 9, 307-317.	1.6	4
150	Payer Policy Behavior Towards Opioid Pharmacotherapy Treatment in Ohio. <i>Journal of Addiction Medicine</i> , 2018, 12, 85-91.	2.6	4
151	Interim methadone – Effective but underutilized: A scoping review. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108766.	3.2	4
152	Improving the Quality of Addiction Treatment. , 2013, , 579-588.		4
153	Recurrent risk of hospitalization among older people with problematic alcohol use: a multiple failure-time analysis with a discontinuous risk model. <i>Addiction</i> , 2022, 117, 2415-2430.	3.3	4
154	Development and implementation of a prescription opioid registry across diverse health systems. <i>JAMIA Open</i> , 2022, 5, .	2.0	4
155	Adoption of practice guidelines and assessment tools in substance abuse treatment. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2010, 5, 4.	2.2	3
156	The National Drug Abuse Treatment Clinical Trials Network: From 2000 to 2020 and beyond. <i>Journal of Substance Abuse Treatment</i> , 2020, 112, 1-3.	2.8	3
157	Effectiveness of and Access to Medications for Opioid Use Disorder for Adolescents and Young Adults: A Scoping Review. <i>Journal of Addiction Medicine</i> , 2022, 16, e157-e164.	2.6	3
158	Perspectives on extended-release naltrexone induction among patients living with HIV and opioid use disorder: a qualitative analysis. <i>Addiction Science &amp; Clinical Practice</i> , 2021, 16, 67.	2.6	3
159	State policy uptake does not require formal action: A comment on Nesoff et al. <i>Addiction</i> , 2022, 117, 2359-2360.	3.3	3
160	Treatment length and outcomes among adolescents: a secondary data analysis. <i>Substance Abuse Treatment, Prevention, and Policy</i> , 2012, 7, 35.	2.2	2
161	A Changing Landscape for Treatment of Alcohol and Drug Use Disorders. <i>American Journal of Public Health</i> , 2019, 109, 838-839.	2.7	2
162	Measurement-based care: the implementation challenge. <i>Addiction</i> , 2019, 114, 1354-1355.	3.3	2

#	ARTICLE	IF	CITATIONS
163	Recommendations to Inform Substance Use Disorder Data Sharing Research: Scoping Review and Thematic Analysis. <i>Journal of Addiction Medicine</i> , 2022, 16, 261-271.	2.6	2
164	Stakeholders in Recovery: Demands, Expectations, and Research Opportunities. <i>Science &amp; Practice Perspectives / A Publication of the National Institute on Drug Abuse, National Institutes of Health</i> , 2005, 3, 34-37.	0.4	2
165	Hospital Admission Rate, Cumulative Hospitalized Days, and Time to Admission Among Older Persons With Substance Use and Psychiatric Conditions. <i>Frontiers in Psychiatry</i> , 2022, 13, 882542.	2.6	2
166	Introduction. <i>Journal of Behavioral Health Services and Research</i> , 2001, 28, 115-117.	1.4	1
167	Crossing the Quality Chasm: Challenges for Counselor Training Programs. <i>Journal of Teaching in the Addictions</i> , 2008, 6, 1-7.	0.3	1
168	Introduction to a Special Issue: Care and treatment for substance use disorders: Studies from around the world. <i>Journal of Substance Abuse Treatment</i> , 2021, , 108620.	2.8	0